Goldman Sachs
NEPH icon

Goldman Sachs’s Nephros NEPH Stock Holding History

Goldman Sachs’s Portfolio NEPH Stock Details NEPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45.8K Sell
12,836
-1,327
-9% -$4.32K ﹤0.01% 6422
2026
Q1 		$42.2K Sell
14,163
-4,817
-25% -$19.2K ﹤0.01% 6308
2025
Q4 		$92.6K Buy
18,980
+337
+2% +$1.72K ﹤0.01% 6200
2025
Q3 		$88.2K Buy
+18,643
New +$73.2K ﹤0.01% 6099
2019
Q4 		– Sell
-19,418
Closed -$156K – 5348
2019
Q3 		$156K Buy
+19,418
New +$142K ﹤0.01% 4886

Other funds holding NEPH

WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CC
Cornerstone Capital Palo Alto, California $1.12B AUM 28.84% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $451M AUM 66.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

Goldman Sachs's NEPH Position: Q2 2026 in Review

Goldman Sachs reduced its Nephros (NEPH) stake by 9.4% in Q2 2026, selling an estimated $4.32K and leaving 12,836 shares worth $45.8K. The position accounts for ﹤0.01% of the portfolio, ranked #6422.

Goldman Sachs first reported a position in NEPH in Q3 2019 and has held it in 5 quarters since. The position peaked at $156K in Q3 2019. 33 funds tracked by Wall St. Rank hold NEPH as of Q2 2026.

  • Goldman Sachs held 12,836 shares of Nephros worth $45.8K as of Q2 2026.
  • Goldman Sachs sold 1,327 Nephros shares in Q2 2026, an estimated $4.32K.
  • Nephros made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #6422 holding.
  • Goldman Sachs first reported a position in Nephros in Q3 2019 and has held it in 5 quarters since.
  • Goldman Sachs's Nephros position peaked at $156K in Q3 2019.
  • 33 funds tracked by Wall St. Rank held Nephros as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.